Positive News SentimentPositive NewsNASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.83 +0.05 (+2.81%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Compugen Stock (NASDAQ:CGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compugen alerts:Sign Up Key Stats Today's Range$1.78▼$1.8450-Day Range$1.63▼$2.1052-Week Range$0.53▼$3.03Volume120,940 shsAverage Volume432,184 shsMarket Capitalization$163.31 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More… AI Expert Reveals New Pick (Ad)Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Compugen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks35th Percentile Overall ScoreCGEN MarketRank™: Compugen scored higher than 35% of companies evaluated by MarketBeat, and ranked 779th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.15 to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.11% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Compugen has recently increased by 15.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.11% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Compugen has recently increased by 15.34%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentCompugen has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Compugen this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Stock News HeadlinesGSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trialSeptember 14, 2024 | msn.comCompugen to Present at Single Cell Genomics 2024 ConferenceSeptember 9, 2024 | prnewswire.comNext opportunity for crypto millionsAs we enter crypto's golden quarter (October-December), this coin is primed for takeoff. The best part? Most investors haven't caught on yet. This is your rare chance to be ahead of the curve. October 6, 2024 | Crypto 101 Media (Ad)Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | prnewswire.comCompugen LtdAugust 27, 2024 | money.usnews.comTruist Financial Keeps Their Buy Rating on Compugen (CGEN)August 16, 2024 | markets.businessinsider.comCompugen Ltd. (CGEN)August 13, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings ForecastsAugust 11, 2024 | finance.yahoo.comSee More Headlines CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.98 on January 1st, 2024. Since then, CGEN stock has decreased by 7.6% and is now trading at $1.83. View the best growth stocks for 2024 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.06. The biotechnology company had revenue of $6.70 million for the quarter, compared to analyst estimates of $2.68 million. How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/06/2024Today10/05/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees68Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+118.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E RatioN/A Forward P/E Ratio12.20 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-1.19% Return on Equity-16.10% Return on Assets-9.23% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual Sales$42.72 million Price / Sales3.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.51Miscellaneous Outstanding Shares89,240,000Free FloatN/AMarket Cap$163.31 million OptionableOptionable Beta2.64 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CGEN) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.